充血性肝病患者晚期肝纤维化评估及肝功能失代偿风险
综述指出,充血性肝病可导致桥接纤维化、失代偿性肝硬化和肝细胞癌,但目前缺乏循证指南指导筛查与管理,现有血清学、影像学、肝硬度及肝活检均难以准确评估肝纤维化或肝功能失代偿风险;MELD-XI是唯一经过验证的血清学预测工具,无创肝硬度测量因所有患者均升高而难以区分淤血与纤维化,肝活检因胶原沉积不均难以标准化且对心脏移植后肝脏结局预测价值有限,肝脏结节因延迟静脉廓清不特异而常需活检确诊。
要点
- 充血性肝病可进展为桥接纤维化、失代偿性肝硬化和肝细胞癌,但目前无循证指南指导筛查与管理。
- MELD-XI是唯一经过验证的血清学工具,用于预测充血性肝病患者的临床结局。
- 无创肝硬度测量在充血性肝病患者中均升高,目前无法区分淤血与纤维化。
核心结论
- 缺乏有效临床工具预测充血性肝病患者的肝纤维化和肝功能,提示需要开发新型生物标志物以协助管理这一复杂疾病。
研究设计与样本
- 综述,纳入充血性肝病相关文献,评估现有临床工具对肝纤维化及肝功能失代偿风险的预测能力,并讨论肝脏结节评估的难点。
主要发现
- MELD-XI评分是唯一经过验证的血清学工具,用于预测充血性肝病患者的临床结局。
- 无创肝硬度测量在充血性肝病患者中均升高,目前无法区分淤血与纤维化,效用有限。
- 肝活检因充血性肝病中胶原沉积不均而难以标准化纤维化分期,且对心脏移植后肝脏结局预测价值有限。
- 充血性肝病中肝脏结节的延迟静脉廓清对肝细胞癌不特异,此类病变可能需活检确诊。
关键数值与推荐
- MELD-XI评分是唯一经过验证的血清学工具,用于预测充血性肝病患者的临床结局。
- 无创肝硬度测量在充血性肝病患者中均升高,目前无法区分淤血与纤维化。
- 肝活检因胶原沉积不均难以标准化纤维化分期,且对心脏移植后肝脏结局预测价值有限。
- 充血性肝病中肝脏结节的延迟静脉廓清对肝细胞癌不特异,此类病变可能需活检确诊。
临床怎么用
- MELD-XI评分可用于预测充血性肝病患者的临床结局。
- 无创肝硬度测量目前无法区分充血性肝病患者的淤血与纤维化。
- 充血性肝病中肝脏结节的延迟静脉廓清对肝细胞癌不特异,此类病变可能需活检确诊。
局限性
- 目前无循证指南指导充血性肝病患者的筛查或管理,部分原因是现有临床工具无法准确评估肝纤维化或肝功能失代偿风险。
- 无创肝硬度测量在充血性肝病患者中均升高,目前无法区分淤血与纤维化。
- 肝活检因充血性肝病中胶原沉积不均而难以标准化纤维化分期,且对心脏移植后肝脏结局预测价值有限。
- 充血性肝病中肝脏结节的延迟静脉廓清对肝细胞癌不特异,此类病变可能需活检确诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Congestive hepatopathy (CH) arises from chronically elevated right-sided heart pressures transmitted to the liver by passive venous congestion. Over time, CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma. Currently, there are no evidence-based guidelines to direct appropriate screening or management of patients with CH, partly because of the inability of current clinical tools (serum tests, imaging studies, liver stiffness measurements, and liver biopsy) to accurately estimate hepatic fibrosis or the risk for hepatic decompensation. The Model for End-Stage Liver Disease excluding international normalized ratio (MELD-XI) score is the only validated serum-based test to predict clinical outcomes in CH. Noninvasive liver stiffness measurements are proving to be of minimal utility as all patients with CH have elevated values that currently cannot differentiate between congestion and fibrosis. In addition, fibrosis staging by liver biopsy is difficult to standardize because of heterogeneous collagen deposition in CH. Moreover, liver biopsy results have little predictive value for post-heart transplant hepatic outcomes in patients with CH. Evaluating liver nodules and masses is also complicated in CH as the finding of delayed venous washout in nodules is not specific for hepatocellular carcinoma in the background of a congested liver, and these lesions may require biopsy to confirm the diagnosis. The lack of effective clinical tools for predicting liver fibrosis and liver function suggests the need for the development of novel biomarkers in patients with CH to assist in the management of this complicated disease. (Hepatology 2018; 00:000-000).
引用
- Lemmer A, VanWagner LB, Ganger D, et al. Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy. Hepatology. 2018. PMID: 29672883. doi:10.1002/hep.30048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。